Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.41 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233298 | 0.76 | PTGDR2 (0.58) | TBXA2RPTGDR2PTGDRCYP2C9DRD2 | |
| SCHEMBL9834116 | 0.71 | RB1 (0.55) | RB1TBXA2RPTGDR2PTGDRPSEN1 | |
| SCHEMBL9594597 | 0.71 | KDM4E (0.58) | RB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2372170 | 0.69 | SMN1; SMN2 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL231853 | 0.67 | PLAU (0.49) | DRD2ADRA1A | |
| SCHEMBL234224 | 0.67 | KDM4E (0.30) | — | |
| SCHEMBL9835353 | 0.67 | SMN1; SMN2 (0.56) | RB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7778999 | 0.66 | RB1 (0.47) | RB1TBXA2RPTGDR2PTGDRPSEN1 | |
| SCHEMBL12332792 | 0.66 | SMN1; SMN2 (0.81) | — | |
| SCHEMBL28111321 | 0.66 | SMN1; SMN2 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915372-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2013-11-20 | — | — | EP | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085820-A2 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MC2R, HRH2, PTGDR | RB1 293/4885TBXA2R 7/4885PTGDR2 9/4885 |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | RB1 3565/4885TBXA2R 6/4885PTGDR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.